Literature DB >> 30829134

Vergence Endurance Test: A Pilot Study for a Concussion Biomarker.

Chang Yaramothu1, Lynn D Greenspan2, Mitchell Scheiman2, Tara L Alvarez1.   

Abstract

The Vergence Endurance Test (VET), a quantitative and objective eye movement assessment, was utilized to differentiate control from concussed subjects. Nine symptomatic concussed (2 male; 30.8 ± 11 years) and 9 asymptomatic control (6 male; 25.1 ± 1.4 years) subjects participated in the VET. Symmetrical disparity vergence step targets were presented with and without visual distractors. A masked data analyst measured vergence latency, peak velocity, response amplitude, settling time, and the percentage of trials which contained blinks. A Binocular Precision Index (BPI) and a Binocular Accuracy Index (BAI) were calculated to quantify the changes that occur in the vergence parameters over the duration of the VET. Convergence and divergence peak velocity, divergence response amplitude, the percentage of trials that contained blinks during the transient portion of the response, and the BAI were significantly (p < 0.05) different between the concussed and the control subjects. For these parameters, the BAI and divergence response amplitude yielded the greatest accuracy, 78%, in their ability to discriminate between the groups. The VET objectively measures the change in vergence performance over time and shows promise as a method to diagnose a concussion. Future studies will determine whether the VET can be used to assess the extent of natural recovery and the effectiveness of therapeutic interventions.

Keywords:  concussion biomarker; objective concussion metric; post-concussion syndrome; vergence distractors; vergence eye movements

Year:  2019        PMID: 30829134      PMCID: PMC6653808          DOI: 10.1089/neu.2018.6075

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  77 in total

1.  Dynamic details of disparity convergence eye movements.

Authors:  T L Alvarez; J L Semmlow; W Yuan; P Munoz
Journal:  Ann Biomed Eng       Date:  1999 May-Jun       Impact factor: 3.934

2.  Disparity vergence double responses processed by internal error.

Authors:  T L Alvarez; J L Semmlow; W Yuan; P Munoz
Journal:  Vision Res       Date:  2000       Impact factor: 1.886

3.  The influence of repetitive eye movements on vergence performance.

Authors:  W Yuan; J L Semmlow
Journal:  Vision Res       Date:  2000       Impact factor: 1.886

4.  Short term modification of disparity vergence eye movements.

Authors:  P Munoz; J L Semmlow; W Yuan; T L Alvarez
Journal:  Vision Res       Date:  1999-05       Impact factor: 1.886

5.  Diffuse axonal injury in mild traumatic brain injury: a diffusion tensor imaging study.

Authors:  Matilde Inglese; Sachin Makani; Glyn Johnson; Benjamin A Cohen; Jonathan A Silver; Oded Gonen; Robert I Grossman
Journal:  J Neurosurg       Date:  2005-08       Impact factor: 5.115

6.  Saccades during symmetrical vergence.

Authors:  Olivier A Coubard; Zoï Kapoula
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-11-22       Impact factor: 3.117

7.  Saccadic behavior during the response to pure vergence stimuli.

Authors:  John Semmlow; Claude Pedrono; Tara L Alvarez
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2007

8.  Relation between fixation disparity and the asymmetry between convergent and divergent disparity step responses.

Authors:  Wolfgang Jaschinski; Aiga Svede; Stephanie Jainta
Journal:  Vision Res       Date:  2007-12-31       Impact factor: 1.886

Review 9.  Update on exercise stress testing.

Authors:  Gerald F Fletcher; Wesley C Mills; Walter C Taylor
Journal:  Am Fam Physician       Date:  2006-11-15       Impact factor: 3.292

10.  Measurement of symptoms following sports-related concussion: reliability and normative data for the post-concussion scale.

Authors:  Mark R Lovell; Grant L Iverson; Michael W Collins; Kenneth Podell; Karen M Johnston; Dustin Pardini; Jamie Pardini; John Norwig; Joseph C Maroon
Journal:  Appl Neuropsychol       Date:  2006
View more
  7 in total

1.  The Convergence Insufficiency Neuro-mechanism in Adult Population Study (CINAPS) Randomized Clinical Trial: Design, Methods, and Clinical Data.

Authors:  Tara L Alvarez; Mitchell Scheiman; Elio M Santos; Cristian Morales; Chang Yaramothu; John Vito D'Antonio-Bertagnolli; Bharat B Biswal; Suril Gohel; Xiaobo Li
Journal:  Ophthalmic Epidemiol       Date:  2019-10-22       Impact factor: 1.648

2.  OculoMotor Assessment Tool: Children Compared with Adults.

Authors:  Rachel Eichler; Gila Mivtachi; Dina Hershkovitz-Azoulay; Mitchell Scheiman; Hadas Ben-Eli
Journal:  Clin Optom (Auckl)       Date:  2022-05-27

3.  OculoMotor Assessment Tool Test Procedure and Normative Data.

Authors:  Chang Yaramothu; Christopher J Morris; John Vito d'Antonio-Bertagnolli; Tara L Alvarez
Journal:  Optom Vis Sci       Date:  2021-06-01       Impact factor: 2.106

4.  Disparity vergence differences between typically occurring and concussion-related convergence insufficiency pediatric patients.

Authors:  Tara L Alvarez; Chang Yaramothu; Mitchell Scheiman; Arlene Goodman; Susan A Cotter; Kristine Huang; Angela M Chen; Matthew Grady; Anne E Mozel; Olivia E Podolak; Chris G Koutures; Christina L Master
Journal:  Vision Res       Date:  2021-04-23       Impact factor: 1.984

5.  Target Eccentricity and Form Influences Disparity Vergence Eye Movements Responses: A Temporal and Dynamic Analysis.

Authors:  Chang Yaramothu; Rajbir S Jaswal; Tara L Alvarez
Journal:  J Eye Mov Res       Date:  2019-12-09       Impact factor: 0.957

6.  Reliability of Frontal Eye Fields Activation and Very Low-Frequency Oscillations Observed during Vergence Eye Movements: an fNIRS Study.

Authors:  Chang Yaramothu; Xiaobo Li; Cristian Morales; Tara L Alvarez
Journal:  Sci Rep       Date:  2020-01-20       Impact factor: 4.379

7.  Reflexive Fusional Vergence and Its Plasticity Are Impaired in Convergence Insufficiency.

Authors:  Ian M Erkelens; William R Bobier
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-08-03       Impact factor: 4.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.